Government to tighten rules on ads for prescription drugs

1. At a Glance

• The Union Health Ministry has proposed a draft amendment to the Drugs Rules, 1945. It would extend the ban on advertising prescription drugs to retailers, wholesalers and distributors, not just manufacturers. [1]
• The covered drugs are those in Schedules H, H1 and X. They may not be advertised without prior sanction of the Central Government. [1][2]
• The stated aim is to close a regulatory gap. The existing rule mainly bound manufacturers, so licensed sellers fell outside it. [1][2]
• Why it matters for UPSC: it touches health regulation (GS-II), consumer protection against misleading ads, antimicrobial resistance (AMR) and self-medication, and commercial speech (Art. 19(1)(a)).

2. Why in the News

• 28 September 2026: A draft amendment to the Drugs Rules, 1945 was notified in the Gazette. It proposes that licence-holders who sell, stock, exhibit, offer for sale or distribute Schedule H, H1 and X drugs cannot advertise them without prior sanction. [1]
• 9–10 October 2026: The proposal was reported as the Health Ministry's push for tighter rules on ads for prescription drugs. [1][2]
• The proposal follows recommendations of the 93rd meeting of the Drugs Technical Advisory Board (DTAB), held on 16 February (2026, as reported). [1]

3. Background & Evolution

• 1945: The Drugs Rules, 1945 were framed. They are the subordinate legislation that sets out schedules, licensing and advertisement conditions for drugs. [1][4]
• 1954: Parliament enacted the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. It is "an Act to control the advertisement of drugs in certain cases" and to prohibit ads of remedies "alleged to possess magic qualities". [3]
• 2015: The Drugs & Cosmetics Rules, 1945 were amended. Since then, no advertisement of Schedule H, H1 and X drugs (prescription drugs) may be made except with the previous sanction of the Central Government. [4]
• 2018–2021: The government addressed misleading ads through PIB-notified mechanisms. These covered AYUSH and herbal "magic remedy" ads and initiatives against misleading ads by pharma companies. [5][6][4]
• 2024: Patanjali came under scrutiny under the Magic Remedies Act, which revived the debate on enforcing drug-ad law. [7]
• 2026: Business Standard reported a growing risk of misleading ads in India's expanding weight-management market. [8] DTAB recommended closing the retailer/distributor gap (Feb), and the draft Gazette notification followed (28 Sept). [1]

4. Core Static Facts

5. Multi-Dimensional Analysis

Legal / Constitutional

• There are two layers of control. The Drugs Rules, 1945 use licence-based and schedule-based restrictions. The DMR Act, 1954 prohibits misleading or "magic" ads. [3][4]
• The amendment is made through delegated legislation: a draft Gazette notification, then public objections, then the final notification. No Act of Parliament is needed. [1]
• Ad restrictions engage Art. 19(1)(a) (commercial speech) and must fit within the Art. 19(2) grounds of public order, decency and morality. Public health is the usual justification. (Analytical point; not drawn from the retrieved sources.)

Social / Public Health

• Schedule H includes commonly used antibiotics. [2] Ads by retailers could encourage self-medication, which feeds AMR.
• Vulnerable, low-literacy consumers are the most exposed to pharmacy-level promotion. This includes online and local ads.

Economic

• The draft affects the business models of retail chains, e-pharmacies and distributors that promote branded prescription products. [1]
• Weight-management and lifestyle drug markets are growing, and ads in this segment carry a higher risk of being misleading. [8]

Ethical / Governance

• The draft closes a regulatory arbitrage: a manufacturer barred from advertising could otherwise promote the same drug through its distribution channel. [1][2]
• It shows DTAB's advisory role shaping rule-making. [1]

Administrative

• Enforcement is split. Licensing of retail and wholesale sale is done by State drug controllers, while ad sanction rests with the Central Government. [4] This makes Centre–State coordination critical.
• Monitoring digital and social-media ads by thousands of licensees is a capacity bottleneck. [5]

6. Recent Developments (last 12–18 months)

• 31 Mar 2026: Reports flagged rising risk of misleading ads as India's weight-management drug market expands. [8]
• 16 Feb 2026: The 93rd DTAB meeting recommended extending the ad restrictions to sellers and distributors. [1]
• 28 Sept 2026: The draft amendment to the Drugs Rules, 1945 was notified in the Gazette. [1]
• 9 Oct 2026: The Health Ministry's proposal for stricter prescription-drug ad rules was reported. [2]

7. Prelims Hooks

• The draft amendment to the Drugs Rules, 1945 was notified on 28 September 2026. [1]
• It extends the prescription-drug ad ban to retailers, wholesalers and distributors. [1]
• The schedules covered are H, H1 and X. [1]
• The proposal arose from the 93rd meeting of DTAB, held on 16 February. [1]
• Since the 2015 amendment, Schedule H/H1/X drugs cannot be advertised without the previous sanction of the Central Government. [4]
• The sanctioning authority for such ads is the Central Government, not State drug controllers. [4]
• Schedule H contains 500+ medicines, including common antibiotics. [2]
• The Drugs and Magic Remedies (Objectionable Advertisements) Act was enacted in 1954. [3]
• The DMR Act bars ads giving a false impression of a drug's true character or making false claims. [3]
• Patanjali faced scrutiny under the DMR Act, 1954 in 2024. [7]
• The proposing ministry is the Ministry of Health & Family Welfare, not the Department of Pharmaceuticals or the Ministry of Consumer Affairs. [1]

8. Why an Ad Ban Will Not Stop Antibiotics Being Sold Over the Counter

• The ad is not where most misuse happens. The shop counter is.
• Schedule H has more than 500 medicines, including common antibiotics. All of them are already meant to be sold only on a doctor's prescription [2].
• The draft only stops sellers from promoting these drugs [1]. It says nothing new about a chemist who sells them without a prescription.

• So a buyer who asks for an antibiotic by name can still get it if the shop does not check. That is the path to self-medication and antimicrobial resistance (AMR — germs that no longer respond to medicines).

• The two jobs sit with two different governments

• The Central Government approves (sanctions) any ad for a Schedule H, H1 or X drug [4].
• State drug controllers license the shops and are supposed to inspect them [4].

• The new rule makes the Centre's job stronger. It does not give states more inspectors to check prescriptions at the counter.

• What this means for an answer: call the draft necessary but narrow. It closes the advertising route and leaves the selling route as it was.

9. Who Can Still Advertise: Influencers and Platforms Without a Licence

• The draft binds licence-holders only
• It covers people who hold a licence to sell, stock, exhibit, offer for sale or distribute these drugs [1].

• A social-media influencer, a health-content creator or a marketing agency usually holds no drug licence. On a plain reading, the new clause does not reach them.

• This matters most in the market the government is worried about

• Misleading ads are a growing risk in India's expanding weight-management market [8].

• Much of that promotion happens through online content, not through ads paid for by a pharmacy.

• The fallback law is weak

• Anyone can still be charged under the DMR Act, 1954 (Drugs and Magic Remedies Act) if an ad is false or misleading [3].
• But that Act only catches false claims. A true but pushy post such as "ask your chemist for drug X to lose weight" may escape the DMR Act and also fall outside the licence-based rule.

10. Why the Penalty Has Not Scared Advertisers So Far

• The punishment in the DMR Act is small
• A first conviction can bring up to six months in jail, a fine, or both. A repeat conviction can bring up to one year [3].

• The Act was written in 1954 [3]. For a large company, a fine like this costs less than one advertising campaign.

• The Patanjali case showed the gap

• On 21 November 2023 the Supreme Court warned Patanjali against claiming its products give permanent cures. It threatened a penalty of Rs 1 crore for each such product [9].
• The company still faced scrutiny afterwards for not keeping its promise to stop misleading ads [9][7].

• The Supreme Court had to step in with its own penalty threat. That shows the regular law was not stopping the ads.

• Lesson for the new rule: widening the list of people covered [1] helps only if a breach costs more than the sales the ad brings in.

11. The Case Against the Ban, and Why It Mostly Fails

• The strongest objection: patients may lose useful price information
• Pharmacy chains and e-pharmacies compete by telling buyers about discounts on medicines they take for a long time, such as drugs for diabetes or blood pressure.
• If "advertisement" is read widely, a simple price list or discount banner could need Central sanction. That could make medicines dearer for patients who already have a prescription.

• Advertising is also commercial speech protected under Art. 19(1)(a) (freedom of speech, which includes ads that sell something).

• What the objection gets right

• Price information is different from promoting a drug. A rule that blocks both goes further than its public-health purpose needs.

• Why the ban still stands

• The drugs covered need a doctor's judgement before use. Schedule H includes antibiotics [2], and misuse of antibiotics harms everyone through AMR, not just the buyer.

• Manufacturers have been under the same prior-sanction rule since 2015 [4]. Leaving sellers out let the same drug be promoted through the shop instead [1][2].

• Balanced line for Mains: keep the ban on promoting the drug. The final rule should say clearly that a plain price list for prescription holders is not an advertisement.

12. What the Health Ministry Should Settle Before the Final Rule

• Health Ministry: define "advertisement" to include online posts
• The draft is still open to objections [1], so the final text can still change.

• Online channels and the weight-loss drug market are where the risk is growing [8]. The definition should clearly cover app banners, sponsored posts and paid influencer content.

• Health Ministry: make the paying company liable, not just the poster

• A licensed seller or manufacturer who pays an unlicensed influencer should be held responsible. Otherwise the gap described above stays open [1].

• Parliament: raise the DMR Act penalties

• The jail terms and fines in the DMR Act are from 1954 [3].

• The Supreme Court's threat of Rs 1 crore per product in the Patanjali case [9] shows the scale of penalty that actually gets an advertiser's attention.

• Centre and States: share information on sanctions

• The Centre gives ad sanctions and states license shops [4]. If each state drug controller can see which ads were approved, it can spot unapproved ads by local licensees.

13. Anchors for Answers

• Data: Schedule H has 500+ medicines, including common antibiotics, all meant to be sold only on prescription [2]
• Report/Committee: 93rd meeting of the Drugs Technical Advisory Board (DTAB), 16 Feb 2026, recommended extending the ad curbs to sellers and distributors [1]
• Law/Case: DMR Act, 1954, Section 7: up to 6 months for a first conviction, up to 1 year for a repeat [3]. Supreme Court in the Patanjali misleading-ads matter (Nov 2023): warned of Rs 1 crore per product [9]. Art. 19(1)(a): commercial speech
• Law/Case: Drugs Rules (2015 amendment): no ad for Schedule H/H1/X drugs without the Central Government's prior sanction [4]

14. Mains Relevance

• GS-II: Government policies and interventions; issues relating to development and management of the Social Sector/Services relating to Health.
• GS-III: Science & technology in everyday life (pharma regulation, AMR).
• GS-IV: Ethics in business and advertising; corporate responsibility towards consumers.
• Possible question stems: 1. India's drug-advertisement regime rests on legislation from the 1940s and 1950s. Examine its adequacy in the age of e-pharmacies and social-media marketing. (GS-II, 15 marks) 2. Extending advertisement curbs on prescription drugs to retailers and distributors is a necessary but insufficient step against self-medication and antimicrobial resistance. Discuss. (GS-II/III) 3. Balance commercial free speech against public health in the regulation of pharmaceutical advertising, with reference to recent regulatory changes. (GS-II/IV)

15. Related Topics to Study Next

• Drugs and Cosmetics Act, 1940 and the CDSCO/DCGI structure: this is the parent framework under which the Drugs Rules and DTAB operate.
• DMR (Objectionable Advertisements) Act, 1954 and the Patanjali case (2024): the parallel misleading-ad statute and its enforcement gaps. [3][7]
• Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024: voluntary or soft regulation of pharma promotion to doctors.
• Antimicrobial Resistance and the Red Line campaign: links Schedule H/H1 antibiotics to the dangers of OTC misuse.
• E-pharmacy regulation (draft rules): the online channel is the main vector for retailer advertising.
• Consumer Protection Act, 2019 and the CCPA's misleading-ad guidelines: a cross-cutting consumer-law remedy.
• Proposed Drugs, Medical Devices and Cosmetics Bill: the effort to replace the 1940 Act.
• AYUSH misleading ads mechanism: an earlier government response to "magic remedy" claims. [5][6]

16. NCERT Concepts to Revise

• Delegated legislation (Polity): The ban is being widened through a draft amendment to rules, made by the executive without a new Act of Parliament.
• Consumer protection (Economy): Curbing misleading prescription-drug ads protects consumers from false claims and unsafe self-medication, which is the core aim of the draft.
• Retailer (Economy): Retailers are newly brought under the ad ban, so knowing their role in the supply chain explains the change.
• Distributor (Economy): Distributors, along with wholesalers, are newly covered, closing the gap that let sellers promote drugs manufacturers could not.
• Manufacturer (Economy): Only manufacturers were bound earlier; the contrast with sellers is the central trap in this topic.
• Arbitrage (Economy): Explains the 'regulatory arbitrage' where a barred manufacturer could still promote the same drug through its sales channel.

17. Common Errors / Trap Areas

• Manufacturers vs sellers: Manufacturers were already barred from advertising Schedule H/H1/X drugs without sanction (2015). [2][4] The 2026 draft adds retail, wholesale and distribution licensees. [1]
• Draft vs final: The 28 Sept 2026 notification is a draft open to objections. It is not yet a final rule. [1]
• Which law: The prior-sanction requirement sits in the Drugs Rules, 1945, not the DMR Act, 1954. The DMR Act targets misleading or magic-cure ads. [3][4]
• Sanctioning authority: Ad sanction comes from the Central Government, not State Licensing Authorities. [4]
• Schedule confusion: Schedule H is prescription drugs (500+, including antibiotics). [2] Schedule H1 is a stricter subset with record-keeping duties. Schedule X is narcotic or psychotropic prescription drugs. (The H1 and X descriptions are general static knowledge and could not be checked against the retrieved sources; verify them against the Drugs Rules text.)